Background Image

Pardee Foundation, Elsa U.

Manager: Cheryl Mirer
Priority: Open

BACKGROUND

Incorporated in 1944 in MI.

Mrs. Pardee provided a $1 million trust fund to promote the cure and control of cancer, mainly through support of research and treatment programs. The donor was the widow of the late James T. Pardee, chairman of Dow Chemical Co. from 1935 to 1941.

FIELDS OF INTEREST

cancer, medical research

LIMITATIONS

No grants to individuals, or for capital campaigns, building, or endowment funds, equipment (except when used in a specific project), scholarships, fellowships, general purposes, matching gifts, or fundraising campaigns; no loans.

FINANCIAL DATA

Total giving: $4,970,989

Qualifying distributions: $5,043,156

Giving activities include:

$4,970,989 for 20 grants (high: $1,800,000; low: $9,700)

SELECTED GRANTS

  • $157,461 to University of Illinois at Chicago, Chicago, IL, in 2012. For study of determining therapeutic value of targeting breast tumor kinase PTK6 in breast cancer
  • $155,214 to University of California, Berkeley, CA, in 2012. For study of potential application of irreversible electroporation (IRE) in treatment of pancreatic cancer
  • $141,049 to University of California, Berkeley, CA, in 2012. For study of novel roles of microRNA let-7C in prostate cancer
  • $131,050 to Yale University, New Haven, CT, in 2012. For study of novel apoptosis inducing therapy targeted to mitochrondria in cancer cells
  • $125,000 to University of Nebraska-Lincoln, Lincoln, NE, in 2012. For study of hpaf1 in drug resistance of ovarian cancer stem cells
  • $125,000 to Pennsylvania State University, University Park, PA, in 2012. For the study of development of novel thiobarbituric acid analogs for lung cancer
  • $124,858 to Johns Hopkins University, Baltimore, MD, in 2012. For study of in vitro and in vivo characterization of miR-675 in esophageal squamous cell carcinomas
  • $123,949 to University of Michigan, Ann Arbor, MI, in 2012. For tumor growth and metastasis in human ovarian cancer
  • $122,627 to University of California, Berkeley, CA, in 2012. For study of roles of autophagy in promoting treatment resistance in giloblastoma
  • $117,399 to University of South Florida, Tampa, FL, in 2012. For study of novel proteasome inhibitors as potential anti-cancer agents